Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Here we aim to boost tumor cell apoptosis induced by CAR T cells and find that anti-B cell maturation antigen (BCMA) CAR T cells over-expressing a granzyme B-NOXA fusion protein show improved killing of multiple myeloma (MM) cells in vitro and in xenograft mouse models in vivo. Mechanistically, such an enhancement is mediated by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. In MM cells, inhibition of MCL-1, an anti-apoptotic factor, by its natural ligand NOXA effectively induces apoptosis. Our data thus show that endowing granzyme B-NOXA expression to CAR T cells improves their killing efficacy, thereby presenting a potential generalizable enhancement for CAR T-mediated anti-cancer immunity.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-05-19
DOI
https://doi.org/10.1038/s41467-025-59818-8
Citations
9
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
9.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Marta Cuenca, Jasmijn Janssen, Angelo D. Meringa, Joost P. G. Sluijter et al.
9 citations
Nature Communications
CAR-T cell therapy research
9.41
article

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Marta Cuenca, Jasmijn Janssen, Angelo D. Meringa, Joost P. G. Sluijter, Benjamin Motais, Zsolt Sebestyén, Corine Pleijte, Anne Slomp, Douwe M. T. Bosma, Niels Bovenschen, Vania Lo Presti, Ralph G. Tieland, Sanne Kroos, Victor Peperzak, Dedeke Rockx-Brouwer, Monique C. Minnema, Sabine Heijhuurs, Jurgen H. E. Kuball, Thomas Kimman, Alain van Mil, Stefan Nierkens, Wendy Boschloo
article en
9 citations

Abstract

Clinical responses with chimeric antigen receptor (CAR) T cells are encouraging, but primary resistance and relapse after therapy prevent durable remission in many patients with cancer, with apoptosis resistance in cancer cells that limits killing by CAR T cells being a potential cause. Here we aim to boost tumor cell apoptosis induced by CAR T cells and find that anti-B cell maturation antigen (BCMA) CAR T cells over-expressing a granzyme B-NOXA fusion protein show improved killing of multiple myeloma (MM) cells in vitro and in xenograft mouse models in vivo. Mechanistically, such an enhancement is mediated by localizing NOXA to cytotoxic granules that are released into cancer cells upon contact. In MM cells, inhibition of MCL-1, an anti-apoptotic factor, by its natural ligand NOXA effectively induces apoptosis. Our data thus show that endowing granzyme B-NOXA expression to CAR T cells improves their killing efficacy, thereby presenting a potential generalizable enhancement for CAR T-mediated anti-cancer immunity.

Nature CommunicationsVol. 16(1)
Utrecht University (NL), University Medical Center Utrecht (NL), Princess Máxima Center (NL)
Universiteit Leiden, KWF Kankerbestrijding
Openalex Percentile: Top 2%
CAR-T cell therapy research
9.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.